Obtainment of 177Lu-DOTA-LANREOTIDE for in vivo studies

被引：0
|
作者：
Nevares, Noemi
Jimenez, Yarissa Villareal
Deluca, Gustavo
Zapata, Miguel
Perez, Juan
Rojo, Ana
Crudo, Jose L.
机构：
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2010年 / 37卷 / 06期
关键词：
D O I：
10.1016/j.nucmedbio.2010.04.074
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：697 / 697
页数：1
相关论文
共 50 条
  • [31] Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
    Sejin Ha
    Yong-il Kim
    Jungsu S. Oh
    Changhoon Yoo
    Baek-Yeol Ryoo
    Jin-Sook Ryu
    EJNMMI Physics, 11
  • [32] Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
    Ha, Sejin
    Kim, Yong-il
    Oh, Jungsu S.
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    Ryu, Jin-Sook
    EJNMMI PHYSICS, 2024, 11 (01)
  • [33] Comparison of tumour and whole body absorbed doses of 177-Lu- DOTA-TATE and Lu-177 DOTA-NOC treatment in the same patient group
    Yeyin, N.
    Kabasakal, L.
    Akyel, R.
    Ocak, M.
    Toklu, T.
    Selcuk, N.
    Demir, M.
    Kanmaz, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S200 - S200
  • [34] Combination of [177Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model
    Simon, Marina
    Jorgensen, Jesper Tranekjaer
    Khare, Harshvardhan A.
    Christensen, Camilla
    Nielsen, Carsten Haagen
    Kjaer, Andreas
    PHARMACEUTICS, 2022, 14 (06)
  • [35] DOTA-conjugation and 177Lu-DOTA-radiolabeling optimizations of IgG4 antibodies
    Jha, P.
    Berglund, H.
    Shojai, T. M.
    Mortensen, A. C. L.
    Nestor, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S676 - S677
  • [36] Lanreotide/lutetium-(177Lu)-oxodotreotide/octreotideLack of efficacy and haematological toxicity
    Reactions Weekly, 2023, 1986 (1) : 233 - 233
  • [37] First comparative dosimetric results after peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTA-NOC and Lu-177 DOTA-TATE
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S373 - S373
  • [38] First comparative dosimetric results after peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTA-NOC and Lu-177 DOTA-TATE
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S179 - S179
  • [39] Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT?
    J. P. Esser
    E. P. Krenning
    J. J. M. Teunissen
    P. P. M. Kooij
    A. L. H. van Gameren
    W. H. Bakker
    D. J. Kwekkeboom
    European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33 : 1346 - 1351
  • [40] Development and Biological Studies of Lu-177-DOTA-rituximab for the Treatment of Non-Hodgkin's Lymphoma
    Massicano, Adriana V. F.
    Pujatti, Priscilla B.
    Alcarde, Lais F.
    Suzuki, Miriam F.
    Spencer, Patrick J.
    Araujo, Elaine B.
    CURRENT RADIOPHARMACEUTICALS, 2016, 9 (01) : 54 - 63
12345